Tuesday’s Midday Movers: Arrowhead Research (ARWR), Clovis Oncology (CLVS), Ambarella (AMBA), Best Buy Co (BBY), Amarin (AMRN)

By Carrie Williams

So far Tuesday, November 26, NASDAQ is down -0.46% and the S&P is up 0.6%. Here are this morning’s most active stocks: Arrowhead Research (ARWRResearch Report), Clovis Oncology (CLVSResearch Report), Ambarella (AMBAResearch Report), Best Buy Co (BBYResearch Report) and Amarin (AMRNResearch Report).

Arrowhead Research is up 13.21% in midday trading to $66.73. Shares opened today at $58.94. The company has a 52-week low of $10.41 and a 52-week high of $67.29. On the Street’s front, the average 12-month analyst price target for the stock is $55.60, marking a -5.67% potential downside from current levels. In a report released yesterday, Robert W. Baird analyst Madhu Kumar upgraded ARWR to Buy, with a price target of $70.00, which implies an upside of 19% from current levels. Separately, on November 19, Cantor Fitzgerald’s Elemer Piros maintained a Hold rating on the stock and has a price target of $50.00. In the last 30 days, insiders purchased $65.65K worth of ARWR shares. Over the last 3 months, the insider sentiment on Arrowhead Research has been negative based on 43 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Clovis Oncology is up 10.49% in midday trading to $11.27. Shares opened today at $10.20. The company has a 52-week low of $2.93 and a 52-week high of $32.05. On the Street’s front, the average 12-month analyst price target for the stock is $11.42, marking a 11.96% potential upside from current levels. In a report issued on November 19, Evercore ISI analyst Joshua Schimmer downgraded CLVS to Hold, with a price target of $8.00, which implies a downside of 22% from current levels. Separately, on November 8, H.C. Wainwright’s Edward White reiterated a Buy rating on the stock and has a price target of $36.00.

Ambarella is down -8.8% in midday trading to $55.06. Shares opened today at $60.37. The company has a 52-week low of $32.31 and a 52-week high of $67.15. On the Street’s front, the average 12-month analyst price target for the stock is $60.13, marking a -0.40% potential downside from current levels. In a report released today, Deutsche Bank analyst Ross Seymore maintained a Hold rating on AMBA, with a price target of $55.00, which reflects a potential downside of -9% from last closing price. Separately, on the same day, Needham’s Quinn Bolton maintained a Sell rating on the stock . Over the last 3 months, the insider sentiment on Ambarella has been negative based on 66 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Best Buy Co is up 7.38% in midday trading to $82.90. Shares opened today at $77.20. The company has a 52-week low of $47.72 and a 52-week high of $82.93. On the Street’s front, the average 12-month analyst price target for the stock is $81.91, marking a 6.10% potential upside from current levels. In a report released today, Wells Fargo analyst Zachary Fadem maintained a Hold rating on BBY, with a price target of $85.00, which implies an upside of 10% from current levels. Separately, on November 8, Piper Jaffray’s Peter Keith maintained a Buy rating on the stock and has a price target of $86.00. Over the last 3 months, the insider sentiment on Best Buy Co has been negative based on 58 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Amarin is down -4.31% in midday trading to $20.29. Shares opened today at $21.20. The company has a 52-week low of $11.78 and a 52-week high of $24.67. On the Street’s front, the average 12-month analyst price target for the stock is $27.50, marking a 29.72% potential upside from current levels. In a report issued on November 22, Jefferies Co. analyst Michael Yee maintained a Buy rating on AMRN. Separately, on November 19, Oppenheimer’s Leland Gershell initiated coverage with a Sell rating on the stock and has a price target of $7.00. In the last 30 days, insiders purchased $29K worth of AMRN shares. Over the last 3 months, the insider sentiment on Amarin has been positive based on 66 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Trending Stocks Based on Insider Activity >>